Olr367 inhibitors represent a specialized category of chemical compounds that are designed to interact with the Olr367 receptor, a specific olfactory receptor belonging to the G-protein coupled receptor (GPCR) superfamily. GPCRs are integral membrane proteins that play a critical role in various physiological processes by transducing extracellular signals into intracellular responses. The Olr367 receptor is one of the many olfactory receptors found in the nasal epithelium, where it is primarily involved in the detection of odor molecules. These receptors are part of a larger family of olfactory receptors that contribute to the complex process of olfaction. Olr367 inhibitors are molecules that can bind to the Olr367 receptor with high specificity, effectively blocking its ability to respond to certain odorants. This inhibition process is typically achieved through competitive binding, where the inhibitor mimics the structure of the natural ligand, preventing the receptor from undergoing the conformational changes necessary for signal transduction.
The study of Olr367 inhibitors provides valuable insights into the molecular mechanisms underlying olfactory perception. By examining how these inhibitors interact with the Olr367 receptor, researchers can gain a deeper understanding of the receptor's structure-activity relationships (SAR). This includes identifying the key amino acid residues involved in ligand binding and receptor activation, as well as elucidating the conformational dynamics of the receptor during the binding process. Additionally, Olr367 inhibitors serve as important tools for probing the functional role of the Olr367 receptor within the broader context of olfactory signaling networks. Through the selective inhibition of this receptor, it is possible to dissect its contribution to olfactory coding, receptor-ligand specificity, and the overall architecture of odorant signal processing. The information gleaned from these studies can further enrich our understanding of GPCR function and the molecular basis of sensory perception, highlighting the intricate interplay between receptor structure and function.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Sunitinib Malate | 341031-54-7 | sc-220177 sc-220177A sc-220177B | 10 mg 100 mg 3 g | $197.00 $520.00 $1093.00 | 4 | |
Inhibits multiple receptor tyrosine kinases, potentially disrupting angiogenesis and tumor cell proliferation. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
CDK4/6 inhibitor, potentially halts cell cycle progression in cancer cells. | ||||||
Pazopanib | 444731-52-6 | sc-396318 sc-396318A | 25 mg 50 mg | $130.00 $182.00 | 2 | |
Inhibits VEGFR, PDGFR, and KIT, potentially disrupting angiogenesis and tumor growth. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
JAK1/2 inhibitor, potentially modulates cytokine signaling involved in myeloproliferative disorders. | ||||||
ABT-199 | 1257044-40-8 | sc-472284 sc-472284A sc-472284B sc-472284C sc-472284D | 1 mg 5 mg 10 mg 100 mg 3 g | $118.00 $337.00 $520.00 $832.00 $1632.00 | 10 | |
BCL-2 inhibitor, potentially induces apoptosis in cancer cells. | ||||||
Ribociclib | 1211441-98-3 | sc-507367 | 10 mg | $450.00 | ||
CDK4/6 inhibitor, potentially arrests cell cycle in hormone receptor-positive breast cancer. | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $209.00 $413.00 | 9 | |
BCR-ABL inhibitor, potentially effective against chronic myeloid leukemia. | ||||||
Vemurafenib | 918504-65-1 | sc-364643 sc-364643A | 10 mg 50 mg | $117.00 $423.00 | 11 | |
BRAF inhibitor, potentially effective against melanoma with BRAF mutations. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $156.00 | 5 | |
BTK inhibitor, potentially affects signaling in B-cell malignancies. | ||||||